GeneSoft Factive Surveillance Program Will Track Appropriate Prescribing
Executive Summary
GeneSoft will track Factive antibiotic prescribing patterns to determine whether labeling adequately promotes short-term use of the drug
You may also be interested in...
FDA Clears 21 NMEs In 2003; Average Approval Time Is 16.6 Months
FDA finished 2003 with slightly more new molecular entity approvals at a slightly faster pace than its 2002 performance
FDA Clears 21 NMEs In 2003; Average Approval Time Is 16.6 Months
FDA finished 2003 with slightly more new molecular entity approvals at a slightly faster pace than its 2002 performance
Factive supplemental approval
FDA approves GeneSoft's Factive (gemifloxacin) for use in community-acquired pneumonia in multi-drug resistant S. pneumoniae strains July 25 (1"The Pink Sheet" April 14, 2003, p. 15)...